Immunome Inc is a biopharmaceutical company focused on developing innovative antibody therapies for the treatment of cancer and other diseases
The company leverages its proprietary platform to identify and isolate antibodies from human immune cells, which are then engineered to target specific antigens linked to various diseases. By harnessing the body's natural immune response, Immunome aims to create therapies that are both effective and safe, with a commitment to improving patient outcomes in oncology and beyond. Through its research and development efforts, Immunome is dedicated to advancing the field of immunotherapy and addressing unmet medical needs.
In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions.
The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the highs of 2021. David Prince, professional trader at T3 Trading Group, joined Benzinga's PreMarket Prep on Tuesday and discussed the biotech industry and Viking Therapeutics and Immunome as notable recent movers.
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Thursday. The Dow traded up 0.68% to 34,081.83 while the NASDAQ fell 0.23% to 13,560.57. The S&P 500, also rose, gaining, 0.28% to 4,389.22.
Gainers Sigilon Therapeutics, Inc. (NASDAQSGTX) shares climbed 523.8% to $24.25 after Eli Lilly agreed to acquire the company for $14.92/share in cash.
